Trial Profile
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir+rilpivirine (Primary) ; Dolutegravir (Primary) ; Dolutegravir/rilpivirine (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms POLAR
- Sponsors ViiV Healthcare
- 26 Feb 2023 Status changed from active, no longer recruiting to completed.
- 24 Oct 2022 Planned End Date changed from 3 Oct 2022 to 31 Jan 2023.
- 07 Sep 2022 Planned End Date changed from 6 Jan 2023 to 3 Oct 2022.